These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 16883016)

  • 1. 18F-FDG small-animal PET for monitoring the therapeutic effect of CT-guided radiofrequency ablation on implanted VX2 lung tumors in rabbits.
    Okuma T; Matsuoka T; Okamura T; Wada Y; Yamamoto A; Oyama Y; Koyama K; Nakamura K; Watanabe Y; Inoue Y
    J Nucl Med; 2006 Aug; 47(8):1351-8. PubMed ID: 16883016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-MicroPET and diffusion-weighted MR image evaluation of early changes after radiofrequency ablation in implanted VX2 tumors in rabbits.
    Ohira T; Okuma T; Matsuoka T; Wada Y; Nakamura K; Watanabe Y; Inoue Y
    Cardiovasc Intervent Radiol; 2009 Jan; 32(1):114-20. PubMed ID: 18696151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase in fluorodeoxyglucose positron emission tomography activity following complete radiofrequency ablation of lung tumors.
    Sharma A; Lanuti M; He W; Palmer EL; Shepard JA; Digumarthy SR
    J Comput Assist Tomogr; 2013; 37(1):9-14. PubMed ID: 23321827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic response to radiofrequency ablation of neoplastic lesions: FDG PET/CT findings.
    Purandare NC; Rangarajan V; Shah SA; Sharma AR; Kulkarni SS; Kulkarni AV; Dua SG
    Radiographics; 2011; 31(1):201-13. PubMed ID: 21257942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: preliminary results.
    Okuma T; Okamura T; Matsuoka T; Yamamoto A; Oyama Y; Toyoshima M; Koyama K; Inoue K; Nakamura K; Inoue Y
    Ann Nucl Med; 2006 Feb; 20(2):115-21. PubMed ID: 16615420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy.
    Paudyal B; Oriuchi N; Paudyal P; Tsushima Y; Iida Y; Higuchi T; Hanaoka H; Miyakubo M; Takano A; Ishikita T; Endo K
    Oncol Rep; 2007 Dec; 18(6):1469-73. PubMed ID: 17982632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Maximum standardized uptake value is more reliable than size measurement in early follow-up to evaluate potential pulmonary malignancies following radiofrequency ablation.
    Alafate A; Shinya T; Okumura Y; Sato S; Hiraki T; Ishii H; Gobara H; Kato K; Fujiwara T; Miyoshi S; Kaji M; Kanazawa S
    Acta Med Okayama; 2013; 67(2):105-12. PubMed ID: 23603927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [18F]Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation: a case report.
    Ludwig V; Hopper OW; Martin WH; Kikkawa R; Delbeke D
    Am Surg; 2003 Jul; 69(7):593-8. PubMed ID: 12889623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of tumoricidal efficacy and response to treatment with 18F-FDG PET/CT after intraarterial infusion with the antiglycolytic agent 3-bromopyruvate in the VX2 model of liver tumor.
    Liapi E; Geschwind JF; Vali M; Khwaja AA; Prieto-Ventura V; Buijs M; Vossen JA; Ganapathy-Kanniappan S; Wahl RL
    J Nucl Med; 2011 Feb; 52(2):225-30. PubMed ID: 21233194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal Scan Time of 18F-FDG PET in Identifying Therapeutic Efficacy Secondary to Radiofrequency Ablation of Lung Cancer: Case Report.
    Zhang WQ; Fu YL; Hu B; Chen S; Yang MF; Li H
    Medicine (Baltimore); 2015 Jun; 94(24):e884. PubMed ID: 26091453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphologic and functional changes in nontumorous liver tissue after radiofrequency ablation in an in vivo model: comparison of 18F-FDG PET/CT, MRI, ultrasound, and CT.
    Vogt FM; Antoch G; Veit P; Freudenberg LS; Blechschmid N; Diersch O; Bockisch A; Barkhausen J; Kuehl H
    J Nucl Med; 2007 Nov; 48(11):1836-44. PubMed ID: 17942811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiofrequency ablation of non-small-cell carcinoma of the lung under real-time FDG PET CT guidance.
    Schoellnast H; Larson SM; Nehmeh SA; Carrasquillo JA; Thornton RH; Solomon SB
    Cardiovasc Intervent Radiol; 2011 Feb; 34 Suppl 2():S182-5. PubMed ID: 20508937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose.
    Tatsumi M; Nakamoto Y; Traughber B; Marshall LT; Geschwind JF; Wahl RL
    Cancer Res; 2003 Oct; 63(19):6252-7. PubMed ID: 14559811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual time-point (18)F-FDG PET/CT to assess response to radiofrequency ablation of lung metastases.
    Lafuente S; Fuster D; Arguis P; Granados U; Perlaza P; Paredes P; Vollmer I; Sánchez M; Lomeña F
    Rev Esp Med Nucl Imagen Mol; 2016; 35(4):226-31. PubMed ID: 26848142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT.
    Nahmias C; Hanna WT; Wahl LM; Long MJ; Hubner KF; Townsend DW
    J Nucl Med; 2007 May; 48(5):744-51. PubMed ID: 17475962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET/CT-guided radiofrequency and cryoablation: is tumor fluorine-18 fluorodeoxyglucose activity dissipated by thermal ablation?
    Sainani NI; Shyn PB; Tatli S; Morrison PR; Tuncali K; Silverman SG
    J Vasc Interv Radiol; 2011 Mar; 22(3):354-60. PubMed ID: 21353987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
    Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
    Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: a comparison with 18F-FDG PET/CT and histology.
    Hyafil F; Cornily JC; Rudd JH; Machac J; Feldman LJ; Fayad ZA
    J Nucl Med; 2009 Jun; 50(6):959-65. PubMed ID: 19443582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer.
    Pauleit D; Zimmermann A; Stoffels G; Bauer D; Risse J; Flüss MO; Hamacher K; Coenen HH; Langen KJ
    J Nucl Med; 2006 Feb; 47(2):256-61. PubMed ID: 16455631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.